



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

## Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,  
Opp. PCI, Ankleshwar – 393 002,  
Gujarat, India

Tel : (02646) 220774

Fax : (02646) 251291

Web: [www.samratpharmachem.com](http://www.samratpharmachem.com) CIN: L24230GJ1992PLC017820

## Corporate Office

701/702, Business Square,  
M. A. Road, Andheri (West),  
Mumbai – 400 058, India.

Tel : (91-22) 26701050/1/2

Fax : (91-22) 26701053

Email: [contact@samratpharmachem.in](mailto:contact@samratpharmachem.in)

**August 14, 2019**

To,  
**Department of Corporate Services,  
BSE Limited**  
P J Towers,  
Dalal Street,  
Mumbai - 400 001.

**Scrip Code: 530125**

Dear Sir,

**Sub: Outcome of the Board Meeting of the Company held today**

We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday, August 14, 2019, the Board has considered and took on record the attached Un-Audited Standalone Financial Results of the Company for the quarter ended June 30, 2019, which is enclosed herewith along with the Limited Review Report of the Statutory Auditor of the Company.

The meeting of the Board of Directors of the Company commenced at 18:00 hrs and concluded at 19:00 hrs.

Kindly inform all your members.

Thanking you,

Yours faithfully,  
**For Samrat Pharmachem Limited**

**Sandeep Prajapati**  
**Company Secretary & Compliance Officer**



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC Phase 4, Ankleshwar 393 002, Gujarat  
 Corp Office : 701/702 Business Square, M. A. Road, Andheri-West, Mumbai 400 058  
 CIN : L24230GJ1992PLC017820

## Statement of Standalone Unaudited Results for the Quarter ended 30 June, 2019

(Rupees in Lakhs)

Particulars	Quarter Ended			Year Ended
	30-Jun-19 (Unaudited)	31-Mar-19 (Audited)	30-Jun-18 (Unaudited)	31-Mar-19 (Audited)
1 (a). Revenue from Operations	3,548.05	3,642.88	2,470.31	11,113.64
(b). Other Income	4.08	17.62	20.97	45.67
Total Revenue	3,552.13	3,660.50	2,491.28	11,159.31
2. Expenditure				
a) Cost of materials consumed	3,212.54	3,220.54	2,352.24	10,353.24
b) Purchase of Traded Goods	0.00	0.00	0.00	0.00
c) Change in Inventories of Finished Goods and Work-in-Progress	-72.89	54.82	-19.89	-90.93
d) Employee Costs	29.07	51.00	27.10	138.36
e) Interest	16.66	34.17	24.33	105.84
f) Depreciation & Amortisation expense	10.53	10.40	10.24	41.77
g) Other Expenses	101.43	120.01	83.29	395.27
Total Expenses	3,297.34	3,490.94	2,477.31	10,943.55
3. Profit before exceptional & extraordinary items & tax	254.79	169.56	13.97	215.76
4. Exceptional Items	0.00	0.00	0.00	0.00
5. Profit before extraordinary items & tax	254.79	169.56	13.97	215.76
6. Extraordinary items	0.00	0.00	0.00	0.00
7. Profit before tax	254.79	169.56	13.97	215.76
8. Tax expense				
a) Current Tax	-63.79	-53.40	-3.60	-61.46
b) Deferred Tax	-3.99	13.92	-6.17	-0.75
Total Tax Expense	-67.78	-39.48	-9.77	-62.21
9. Profit (Loss) for the period after tax	187.01	130.08	-4.20	153.55
10. Other Comprehensive Income (OCI)				
a(i) Items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00
b(i) Items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00
Total Other comprehensive income, net of income tax	0.00	0.00	0.00	0.00
11. Total Comprehensive Income for the period	187.01	130.08	-4.20	153.55
12. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97
13. Earnings per equity share				
a) Basic	6.05	4.21	0.14	4.97
b) Diluted	6.05	4.21	0.14	4.97

### Notes:

- The above results were reviewed by the Audit Committee of the Board of Directors.
- The Statutory Auditors have carried out a limited review of the results for the quarter ended 30 June, 2019
- The above unaudited results have been taken on record by the Board of Directors at its Meeting held on Wednesday, 14 August 2019 at the Corporate Office of the Company.
- Figures for the previous period have been regrouped / reclassified, wherever necessary.

By order of the Board of Directors  
 For Samrat Pharmachem Limited

Rajesh Mehta  
 Executive Director  
 DIN: 00216731

Place : Mumbai  
 Date : 14 August 2019



# Shah & Savla LLP

Chartered Accountants

CA Mulesh Savla  
Advisory & Regulatory

CA Nilesh Dedhia  
Direct Tax & Litigation

CA Miral Nagda  
Audit & Assurance


CA Nihar Dharod  
Indirect Tax & Litigation

## LIMITED REVIEW REPORT

**To Board of Directors  
Samrat Pharmachem Limited**

1. We have reviewed the accompanying statement of unaudited financials result of Samrat Pharmachem Limited, for the Quarter ended 30<sup>th</sup> June, 2019 attached herewith being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. This statement is responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors. Our responsibility is to issue a report on these financials statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim financial information performed by Independent Auditor of the entity". A review of interim financial information consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.
3. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting policies and practices has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and rules made there under, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For SHAH & SAVLA LLP  
Chartered Accountants  
Firm Reg: No.:109364W/W100143**

  
**CA. Miral H. Nagda  
(Partner)  
Membership No. 108135**



**Place: Mumbai  
Date: 14 AUG 2019**

UDIN : 19108135 AAAABL2068